List view / Grid view

Shi-Yong Sun (Emory University School of Medicine and Winship Cancer Institute)



Can mTOR kinase inhibitors beat rapalogues in fighting against cancer?

19 February 2014 | By

The mammalian target of rapamycin (mTOR) has emerged as a promising cancer therapeutic target. Some rapamycin analogues (rapalogues) as mTOR allosteric inhibitors are FDA-approved drugs for treatment of certain types of cancers. However, the modest clinical anticancer activity of rapalogues, which preferentially inhibit mTOR complex 1, in most types of…